Social Media Ideas for Biocon

Pharma Stock Jumps After Securing ₹515 Cr Contracts from Malaysia’s Ministry of Health

Synopsis: Biocon strengthened its Malaysia presence after partner Duopharma secured insulin contracts worth over ₹514 crore, supporting affordable diabetes treatment and expanding...

Biocon slips despite BBL turning wholly-owned subsidiary

On Monday, Biocon completed the acquisition of 1,15,36,956 equity shares of Biocon Biologics from 127 selling shareholders, making BBL a wholly-owned subsidiary with effect from th...

Biocon founder Kiran Mazumdar-Shaw says India needs patient capital for Biotech

Biocon founder says India has the talent and scientific capability to build global biotech champions, but lacks the funding ecosystem needed to scale them

Biocon shares jump 6% as Mylan likely exits drugmaker after Rs 3,481 crore stake sale

Biocon shares experienced a significant jump of over 6% on Tuesday. Viatris-owned Mylan intends to sell a substantial stake, exiting the Indian drugmaker. This stake sale represent...

Ipca inks licensing agreement with Bhami Research for biologics delivery platform access

Licencing agreement grants Ipca access to Bhami Research’s proprietary high-concentration subcutaneous biologics delivery platform for the development and commercialisation of mult...

Kiran Mazumdar-Shaw founded Immuneel Therapeutics raises Rs 100 Cr in Series B Funding

Immuneel Therapeutics will utilise the funding round for multiple initiatives that include expanding manufacturing capacity, R&D and international expansion.

Why Is Concord Biotech Stock Up by 8% Today?

Synopsis: Concord Biotech Ltd shares jumped 8% after USFDA approval for its ANDA of Mycophenolate Mofetil oral suspension (200 mg/mL). The drug is an immunosuppressant for transpla...

'GLP-1 alters...': Kiran Mazumdar-Shaw sounds caution as Nithin Kamath flags weak drug demand

Kamath believes affordability is no longer the biggest obstacle. According to him, convincing people to remain on a weekly injection indefinitely is proving to be a much harder pro...

Beigene

Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Shantha Biologics to provide cartridge fill-finish services for Novo Nordisk

Novo Nordisk India rolls-out once-weekly basal insulin Awiqli

The product will be imported from Denmark and is priced at ₹2611 for a 1 ml pen (700 insulin units)

BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO - Slideshow

Novo Nordisk Launches Awiqli, World’s First Weekly Basal Insulin In India

Novo Nordisk has launched Awiqli (insulin icodec), the world’s first once-weekly basal insulin, in India. The company says the therapy could reduce the injection burden from 365 to...

MSCI Review On August 12: Laurus Labs, Biocon Emerge As Strongest Candidates

Among the likely beneficiaries, Laurus Labs and Biocon have been assigned a high probability of moving from the MSCI India Small Cap Index to the MSCI India Standard Index.

InduPro Licenses Lonza’s Linker Payload Technologies and Bioconjugation Platforms

Lonza and InduPro signed the licensing agreement to develop differentiated therapeutic approaches designed to address complex diseases such as cancer, where precision targeting and...

Dr Reddy's Launches Oral Semaglutide Biosimilar Obeda In India

Oral semaglutide, a glucagon-Like Peptide-1 receptor agonist (GLP-1 RA), is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes...

Sun Pharma to acquire Innovcare Lifesciences in ₹271 crore deal

GVRP, StepsBio set up CoE for formulations R&D in Bengaluru

GSRC is designed to tackle complex formulation challenges by combining advanced scientific infrastructure with specialised workflows for drug delivery systems, sterile injectables,...

IPCA Labs, Biocon, Laurus Labs, Gland Pharma, Aurobindo, Sun Pharma shares hit 52-week highs; what's next?

Other pharma stocks, including Wockhardt Ltd, Lupin Ltd, Divi's Laboratories Ltd, Zydus Lifesciences Ltd, Torrent Pharmaceuticals Ltd, JB Chemicals & Pharmaceuticals Ltd, Manki...

From Discovery to Development in Emerging Modalities

ProBio is building flexible platforms for multispecific antibodies, ADCs, and other advanced therapeutic approaches. The post From Discovery to Development in Emerging Modalities a...

Multibagger Ashish Kacholia Stock in Which DIIs Nearly Tripled Their Stake to Keep on Your Radar

Synopsis: Institutional investors nearly tripled their stake in a Himachal Pradesh-based oncology pharma company in a single quarter, even as the stock rallied sharply – a vote of...

Oncology startup 4baseCare closes Rs 128 Cr Series B round

4baseCare said the proceeds will be used to accelerate its global expansion, strengthen its genomics laboratory network, and scale its AI-powered precision oncology platform, OncoT...

India's biotech push reaches an inflection point, but funding remains the missing piece

Historically, Indian pharmaceutical companies have focused on generics and services businesses, which carry lower risk and shorter development

BridgeBio

BridgeBio Anonymous (not verified) Thu, 07/09/2026 - 09:10 field_thread_url https://cafepharma.com/boards/threads/bridgebio.698762/ boar...